organization · Reporting owner

COLUMN GROUP III-A, LP

Disclosed activity across 5 companies

Tapewire entity: 64488
SEC CIK: 0001668085

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
CONSTELLATION PHARMACEUTICALS INCCNST · Entity 137050	10% owner	February 17, 2021	February 19, 2021
NGM BIOPHARMACEUTICALS INCNGM · Entity 11997	10% owner	April 05, 2024	April 08, 2024
Revolution Medicines, Inc.RVMD · Entity 606	10% owner	November 16, 2020	November 18, 2020
Surrozen, Inc./DESRZN · Entity 6092	10% owner	January 15, 2026	January 20, 2026
Tenaya Therapeutics, Inc.TNYA · Entity 6506	10% owner	February 24, 2026	February 26, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

CONSTELLATION PHARMACEUTICALS INC

Report date February 17, 2021 · Filed February 19, 2021

Jointly reported with COLUMN GROUP L P, COLUMN GROUP III, LP, COLUMN GROUP III GP, LP, COLUMN GROUP GP, LP, PONOI CAPITAL, LP, Ponoi Management, LLC, Ponoi Capital II, LP, Ponoi II Management, LLC, Kutzkey Tim

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	99,155	Reported balance After 2021-02-17 transaction · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · 2021-02-17 · Sale · Disposed 10,000 · Balance 99,155 F1: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $36.95 to $37.005, inclusive. The David V. and Alena Z. Goeddel 2004 Trust undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2: These securities are held directly by The David V. and Alena Z. Goeddel 2004 Trust.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	1,880,623	Reported balance Holding disclosure · report date 2021-02-17 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 1,880,623 F4: The securities are directly held by Ponoi Capital, LP ("Ponoi LP"). Ponoi Management, LLC ("Ponoi LLC") is the general partner of Ponoi LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson, and Tim Kutzkey (collectively, the "Ponoi Managing Partners"). The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. Ponoi LLC and the each of the Ponoi Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares
Common StockSEC Table I · non-derivative	IndirectSee Footnote	1,574,229	Reported balance Holding disclosure · report date 2021-02-17 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 1,574,229 F5: The securities are directly held by Ponoi Capital II, LP ("Ponoi II LP"). Ponoi II Management, LLC ("Ponoi II LLC") is the general partner of Ponoi II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of Ponoi II LLC are the Ponoi Managing Partners. The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. Ponoi II LLC and the each of the Ponoi Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	19,571	Reported balance Holding disclosure · report date 2021-02-17 · row 5 Holding and transaction disclosures are not merged. 1 source row Row 5 · Balance 19,571 F6: The securities are directly held by The Column Group III, LP ("TCG III LP"). The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Ponoi Managing Partners. The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG III GP and each of the Ponoi Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	22,103	Reported balance Holding disclosure · report date 2021-02-17 · row 6 Holding and transaction disclosures are not merged. 1 source row Row 6 · Balance 22,103 F7: The securities are directly held by The Column Group III- A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Ponoi Managing Partners. The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG III GP and each of the Ponoi Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	50,000	Reported balance Holding disclosure · report date 2021-02-17 · row 7 Holding and transaction disclosures are not merged. 1 source row Row 7 · Balance 50,000 F8: These securities are held directly by the Alena Goeddel Irrevocable Trust
Common StockSEC Table I · non-derivative	Direct	2,584,957	Reported balance Holding disclosure · report date 2021-02-17 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 2,584,957 F3: These securities are directly held by The Column Group, LP ("TCG LP"). The Column Group GP, LP ("TCG GP") is the general partner of TCG LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG GP are David Goeddel and Peter Svennilson (collectively, the "TCG Managing Partners"). The TCG Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG GP and each of the TCG Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $36.95 to $37.005, inclusive. The David V. and Alena Z. Goeddel 2004 Trust undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.

F2: These securities are held directly by The David V. and Alena Z. Goeddel 2004 Trust.

F3: These securities are directly held by The Column Group, LP ("TCG LP"). The Column Group GP, LP ("TCG GP") is the general partner of TCG LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG GP are David Goeddel and Peter Svennilson (collectively, the "TCG Managing Partners"). The TCG Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG GP and each of the TCG Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

F4: The securities are directly held by Ponoi Capital, LP ("Ponoi LP"). Ponoi Management, LLC ("Ponoi LLC") is the general partner of Ponoi LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson, and Tim Kutzkey (collectively, the "Ponoi Managing Partners"). The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. Ponoi LLC and the each of the Ponoi Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares

F5: The securities are directly held by Ponoi Capital II, LP ("Ponoi II LP"). Ponoi II Management, LLC ("Ponoi II LLC") is the general partner of Ponoi II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of Ponoi II LLC are the Ponoi Managing Partners. The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. Ponoi II LLC and the each of the Ponoi Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

F6: The securities are directly held by The Column Group III, LP ("TCG III LP"). The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Ponoi Managing Partners. The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG III GP and each of the Ponoi Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

F7: The securities are directly held by The Column Group III- A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Ponoi Managing Partners. The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG III GP and each of the Ponoi Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

F8: These securities are held directly by the Alena Goeddel Irrevocable Trust

NGM BIOPHARMACEUTICALS INC

Report date April 05, 2024 · Filed April 08, 2024

Jointly reported with COLUMN GROUP GP, LP, COLUMN GROUP III, LP, COLUMN GROUP III GP, LP, Column Group IV, LP, Column Group IV-A, LP, Column Group IV GP, LP, TCG IV GP, LLC, Column Group Opportunity III, LP, Column Group Opportunity III GP, LP

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnotes	0	Reported balance After 2024-04-05 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2024-04-05 · Disposition to issuer · Disposed 949,862 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F3: The securities were directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG Managing Members"). (cont'd in FN 3) F4: (cont'd from FN 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2024-04-05 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2024-04-05 · Disposition to issuer · Disposed 2,650,177 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F5: The securities were directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG IV GP LLC ("TCG IV LLC") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG IV LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2024-04-05 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2024-04-05 · Disposition to issuer · Disposed 90,442 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F6: The securities were directly held by The Column Group IV-A, LP ("TCG IV-A LP"). TCG IV GP LP is the general partner of TCG IV-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG IV LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2024-04-05 transaction · row 5 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 5 · 2024-04-05 · Disposition to issuer · Disposed 858,035 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F8: The securities were directly held by The Column Group III, LP ("TCG III LP"). The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG III GP and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2024-04-05 transaction · row 6 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 6 · 2024-04-05 · Disposition to issuer · Disposed 968,990 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F9: The securities were directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG III GP and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2024-04-05 transaction · row 7 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 7 · 2024-04-05 · Disposition to issuer · Disposed 2,265,758 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F10: The securities were directly held by The Column Group II, LP ("TCG II LP"). TCG II GP is the general partner of TCG II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG II GP are the TCG Managing Partners. The TCG Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG II GP and each of the TCG Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2024-04-05 transaction · row 8 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 8 · 2024-04-05 · Disposition to issuer · Disposed 1,298,908 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F11: The securities were directly held by Ponoi Capital, LP ("Ponoi LP"). Ponoi Management, LLC ("Ponoi LLC") is the general partner of Ponoi LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of Ponoi LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. Ponoi LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2024-04-05 transaction · row 9 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 9 · 2024-04-05 · Disposition to issuer · Disposed 1,298,908 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F12: The securities were directly held by Ponoi Capital II, LP ("Ponoi II LP"). Ponoi II Management, LLC ("Ponoi II LLC") is the general partner of Ponoi II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of Ponoi II LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. Ponoi II LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2024-04-05 transaction · row 10 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 10 · 2024-04-05 · Disposition to issuer · Disposed 100,000 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F13: The securities were directly held by TCG GP. The managing members of TCG GP are the TCG Managing Partners. The TCG Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. Each of the TCG Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2024-04-05 transaction · row 11 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 11 · 2024-04-05 · Disposition to issuer · Disposed 100,000 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F14: The securities were directly held by The Column Group Management LP ("TCGM LP"). The managing partners of TCGM LP are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. Each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2024-04-05 transaction · row 12 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 12 · 2024-04-05 · Disposition to issuer · Disposed 15,000 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F15: The securities were owned solely by Tim Kutzkey.
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2024-04-05 transaction · row 13 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 13 · 2024-04-05 · Disposition to issuer · Disposed 44,000 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F16: The securities were directly held by Peter Svennilson.
Common StockSEC Table I · non-derivative	IndirectSee footnote	1,000	Reported balance After 2024-04-05 transaction · row 14 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 14 · 2024-04-05 · Other · Acquired 1,000 · Balance 1,000 F17: At the Effective Time, Purchaser merged with and into the Issuer pursuant to Section 251(h) of the Delaware General Corporation Law, with the Issuer surviving as a wholly-owned subsidiary of the Parent. As a result, Parent holds all of the issued and outstanding shares of common stock (equaling 1,000 shares) of the Issuer. TCG LP owns 28.1% of Parent and is the general partner of Parent. Peter Svennilson and Dr. Goeddel are the managing partners of TCG GP, which is the general partner of TCG LP.
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2024-04-05 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 4 · 2024-04-05 · Disposition to issuer · Disposed 11,103,333 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F7: The securities were directly held by The Column Group, LP ("TCG LP").The Column Group GP, LP ("TCG GP") is the general partner of TCG LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG GP are David Goeddel, a member of the Issuer's board of directors and Peter Svennilson (collectively, the "TCG Managing Partners"). The TCG Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG GP and each of the TCG Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

Filing footnotes · ownership attribution and instrument terms

F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2)

F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements.

F3: The securities were directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG Managing Members"). (cont'd in FN 3)

F4: (cont'd from FN 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F5: The securities were directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG IV GP LLC ("TCG IV LLC") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG IV LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F6: The securities were directly held by The Column Group IV-A, LP ("TCG IV-A LP"). TCG IV GP LP is the general partner of TCG IV-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG IV LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F7: The securities were directly held by The Column Group, LP ("TCG LP").The Column Group GP, LP ("TCG GP") is the general partner of TCG LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG GP are David Goeddel, a member of the Issuer's board of directors and Peter Svennilson (collectively, the "TCG Managing Partners"). The TCG Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG GP and each of the TCG Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F8: The securities were directly held by The Column Group III, LP ("TCG III LP"). The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG III GP and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F9: The securities were directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG III GP and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F10: The securities were directly held by The Column Group II, LP ("TCG II LP"). TCG II GP is the general partner of TCG II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG II GP are the TCG Managing Partners. The TCG Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG II GP and each of the TCG Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F11: The securities were directly held by Ponoi Capital, LP ("Ponoi LP"). Ponoi Management, LLC ("Ponoi LLC") is the general partner of Ponoi LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of Ponoi LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. Ponoi LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F12: The securities were directly held by Ponoi Capital II, LP ("Ponoi II LP"). Ponoi II Management, LLC ("Ponoi II LLC") is the general partner of Ponoi II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of Ponoi II LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. Ponoi II LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F13: The securities were directly held by TCG GP. The managing members of TCG GP are the TCG Managing Partners. The TCG Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. Each of the TCG Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F14: The securities were directly held by The Column Group Management LP ("TCGM LP"). The managing partners of TCGM LP are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. Each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F15: The securities were owned solely by Tim Kutzkey.

F16: The securities were directly held by Peter Svennilson.

F17: At the Effective Time, Purchaser merged with and into the Issuer pursuant to Section 251(h) of the Delaware General Corporation Law, with the Issuer surviving as a wholly-owned subsidiary of the Parent. As a result, Parent holds all of the issued and outstanding shares of common stock (equaling 1,000 shares) of the Issuer. TCG LP owns 28.1% of Parent and is the general partner of Parent. Peter Svennilson and Dr. Goeddel are the managing partners of TCG GP, which is the general partner of TCG LP.

Revolution Medicines, Inc.

Report date November 16, 2020 · Filed November 18, 2020

Jointly reported with COLUMN GROUP III, LP, COLUMN GROUP III GP, LP, PONOI CAPITAL, LP, Ponoi Capital II, LP, Ponoi Management, LLC, Ponoi II Management, LLC, Kutzkey Tim, GOEDDEL DAVID V

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	2,151,026	Reported balance After 2020-11-16 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2020-11-16 · Sale · Disposed 952,023 · Balance 2,151,026 F1: The securities are directly held by The Column Group III, LP ("TCG III LP"). The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are David Goeddel, Peter Svennilson, a member of the Issuer's board of directors, and Tim Kutzkey (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares
Common StockSEC Table I · non-derivative	IndirectSee Footnote	2,429,180	Reported balance After 2020-11-16 transaction · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · 2020-11-16 · Sale · Disposed 1,075,133 · Balance 2,429,180 F2: The securities are directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares
Common StockSEC Table I · non-derivative	IndirectSee Footnote	685,011	Reported balance Holding disclosure · report date 2020-11-16 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 685,011 F3: The securities are directly held by Ponoi Capital, LP ("Ponoi LP"). Ponoi Management, LLC ("Ponoi LLC") is the general partner of Ponoi LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of Ponoi II LLC are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such shares. Ponoi LLC and the each of the Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares
Common StockSEC Table I · non-derivative	IndirectSee Footnote	685,011	Reported balance Holding disclosure · report date 2020-11-16 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 685,011 F4: The securities are directly held by Ponoi Capital II, LP ("Ponoi II LP"). Ponoi II Management, LLC ("Ponoi II LLC") is the general partner of Ponoi II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of Ponoi II LLC are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such shares. Ponoi II LLC and the each of the Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

Filing footnotes · ownership attribution and instrument terms

F1: The securities are directly held by The Column Group III, LP ("TCG III LP"). The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are David Goeddel, Peter Svennilson, a member of the Issuer's board of directors, and Tim Kutzkey (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares

F2: The securities are directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares

F3: The securities are directly held by Ponoi Capital, LP ("Ponoi LP"). Ponoi Management, LLC ("Ponoi LLC") is the general partner of Ponoi LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of Ponoi II LLC are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such shares. Ponoi LLC and the each of the Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares

F4: The securities are directly held by Ponoi Capital II, LP ("Ponoi II LP"). Ponoi II Management, LLC ("Ponoi II LLC") is the general partner of Ponoi II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of Ponoi II LLC are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such shares. Ponoi II LLC and the each of the Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

Surrozen, Inc./DE

Report date January 15, 2026 · Filed January 20, 2026

Jointly reported with COLUMN GROUP III GP, LP, COLUMN GROUP III, LP, Column Group Opportunity III, LP, Column Group Opportunity III GP, LP, TCG Opportunity III GP, LLC, Svennilson Peter

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy The Column Group III, LP	900,292	Last balance in matching sequence After 2026-01-20 transaction · row 5 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 3 source rows Row 1 · 2026-01-15 · Purchase · Acquired 5,590 · Balance 890,604 F1: The securities are directly held by The Column Group III, LP ("TCG III LP"). The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Row 3 · 2026-01-16 · Purchase · Acquired 1,204 · Balance 891,808 F1: The securities are directly held by The Column Group III, LP ("TCG III LP"). The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Row 5 · 2026-01-20 · Purchase · Acquired 8,484 · Balance 900,292 F1: The securities are directly held by The Column Group III, LP ("TCG III LP"). The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectBy The Column Group III-A, LP	1,016,658	Last balance in matching sequence After 2026-01-20 transaction · row 6 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 3 source rows Row 2 · 2026-01-15 · Purchase · Acquired 6,303 · Balance 1,005,732 F2: The securities are directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Row 4 · 2026-01-16 · Purchase · Acquired 1,358 · Balance 1,007,090 F2: The securities are directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Row 6 · 2026-01-20 · Purchase · Acquired 9,568 · Balance 1,016,658 F2: The securities are directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectBy The Column Group Opportunity III, LP	344,827	Reported balance Holding disclosure · report date 2026-01-15 · row 7 Holding and transaction disclosures are not merged. 1 source row Row 7 · Balance 344,827 F3: The securities are directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are the Managing Partners. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

Filing footnotes · ownership attribution and instrument terms

F1: The securities are directly held by The Column Group III, LP ("TCG III LP"). The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F2: The securities are directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F3: The securities are directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are the Managing Partners. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

Tenaya Therapeutics, Inc.

Report date February 24, 2026 · Filed February 26, 2026

Jointly reported with COLUMN GROUP III GP, LP, COLUMN GROUP III, LP, Column Group Opportunity III, LP, Column Group Opportunity III GP, LP, TCG Opportunity III GP, LLC, Kutzkey Tim, Svennilson Peter

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	1,649,281	Reported balance After 2026-02-24 transaction · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · 2026-02-24 · Sale · Disposed 309,228 · Balance 1,649,281 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.584 to $0.6392, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F2: The securities are directly held by The Column Group III, LP ("TCG III LP"). TCG III GP is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are Peter Svennilson and Tim Kutzkey (together, the "Managing Partners"). The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	1,862,545	Reported balance After 2026-02-24 transaction · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · 2026-02-24 · Sale · Disposed 349,212 · Balance 1,862,545 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.584 to $0.6392, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F3: The securities are directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	0	Reported balance After 2026-02-25 transaction · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · 2026-02-25 · Sale · Disposed 1,649,281 · Balance 0 F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.55 to $0.641, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F2: The securities are directly held by The Column Group III, LP ("TCG III LP"). TCG III GP is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are Peter Svennilson and Tim Kutzkey (together, the "Managing Partners"). The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	0	Reported balance After 2026-02-25 transaction · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · 2026-02-25 · Sale · Disposed 1,862,545 · Balance 0 F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.55 to $0.641, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F3: The securities are directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	49,313,559	Reported balance Holding disclosure · report date 2026-02-24 · row 5 Holding and transaction disclosures are not merged. 1 source row Row 5 · Balance 49,313,559 F5: The securities are directly held by TCG Opportunity III LP. The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are the Managing Partners. The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.584 to $0.6392, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F2: The securities are directly held by The Column Group III, LP ("TCG III LP"). TCG III GP is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are Peter Svennilson and Tim Kutzkey (together, the "Managing Partners"). The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

F3: The securities are directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.55 to $0.641, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F5: The securities are directly held by TCG Opportunity III LP. The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are the Managing Partners. The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
March 26, 2025 Filed Mar 28, 2025 20:57 UTC	Surrozen, Inc./DE SRZN · Entity 6092	PurchaseCommon Stock	323,886	$11.60	$3,757,077.60	Disclosure SEC source: 0000950170-25-047104 · ownership.xml · nonDerivative · entry 1 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group III, LP Disclosed balance after: 704,332 F1 · price: Represents a price per unit, consisting of (i) $11.5375 per share of the Issuer's Common Stock and (ii) $0.0625 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which The Column Group III, LP ("TCG III LP"), The Column Group III-A, LP ("TCG III-A LP") and The Column Group Opportunity III, LP ("TCG Opportunity III LP") purchased in the Issuer's private placement on March 24, 2025 (the "2025 Private Placement"). F2 · balance_after: The amount beneficially owned by the Reporting Persons, has been updated to correct an administrative error in previously reported Form 4s. F3 · ownership.nature: The securities are directly held by TCG III LP. The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
March 05, 2025 Filed Mar 7, 2025 19:14 UTC	Tenaya Therapeutics, Inc. TNYA · Entity 6506	PurchaseSeries B Warrant (right to buy) · Derivative	17,857,142	Not disclosed Strike: $0.70	Not disclosed	Disclosure SEC source: 0000950170-25-035789 · ownership.xml · derivative · entry 5 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 17,857,142 Underlying: Common Stock · 17,857,142 shares Expires 2026-06-30 F1 · price: Pursuant to an underwritten public offering, The Column Group Opportunity III, LP ("TCG Opportunity III LP") purchased units (the "Units") at a price per Unit of $0.70 per Unit. Each Unit consists of (a) one share of the Issuer's common stock, par value $0.0001 per share (the "Common Stock", and such shares, the "Shares"), (b) one Series A warrant to purchase one share of Common Stock at an exercise price of $0.80 per share which will expire five years from the date of issuance (a "Series A Warrant") and (c) one half of a Series B warrant to purchase a share of Common Stock at an exercise price of $0.70 per share that will expire on June 30, 2026 (a "Series B Warrant"). F7 · derivative.exercise_date: Each Series B Warrant is immediately exercisable (subject to certain beneficial ownership limitations). F2 · ownership.nature: The securities are directly held by TCG Opportunity III LP. The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the Issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "Managing Partners"). F3 · ownership.nature: (Continued from Footnote 2) The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
March 05, 2025 Filed Mar 7, 2025 19:14 UTC	Tenaya Therapeutics, Inc. TNYA · Entity 6506	PurchaseSeries A Warrant (right to buy) · Derivative	35,714,284	Not disclosed Strike: $0.80	Not disclosed	Disclosure SEC source: 0000950170-25-035789 · ownership.xml · derivative · entry 4 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 35,714,284 Underlying: Common Stock · 35,714,284 shares Expires 2030-03-04 F1 · price: Pursuant to an underwritten public offering, The Column Group Opportunity III, LP ("TCG Opportunity III LP") purchased units (the "Units") at a price per Unit of $0.70 per Unit. Each Unit consists of (a) one share of the Issuer's common stock, par value $0.0001 per share (the "Common Stock", and such shares, the "Shares"), (b) one Series A warrant to purchase one share of Common Stock at an exercise price of $0.80 per share which will expire five years from the date of issuance (a "Series A Warrant") and (c) one half of a Series B warrant to purchase a share of Common Stock at an exercise price of $0.70 per share that will expire on June 30, 2026 (a "Series B Warrant"). F6 · derivative.exercise_date: Each Series A Warrant is immediately exercisable (subject to certain beneficial ownership limitations). F2 · ownership.nature: The securities are directly held by TCG Opportunity III LP. The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the Issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "Managing Partners"). F3 · ownership.nature: (Continued from Footnote 2) The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
March 05, 2025 Filed Mar 7, 2025 19:14 UTC	Tenaya Therapeutics, Inc. TNYA · Entity 6506	PurchaseCommon Stock	35,714,284	$0.70	$24,999,998.80	Disclosure SEC source: 0000950170-25-035789 · ownership.xml · nonDerivative · entry 1 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 49,313,559 F1 · price: Pursuant to an underwritten public offering, The Column Group Opportunity III, LP ("TCG Opportunity III LP") purchased units (the "Units") at a price per Unit of $0.70 per Unit. Each Unit consists of (a) one share of the Issuer's common stock, par value $0.0001 per share (the "Common Stock", and such shares, the "Shares"), (b) one Series A warrant to purchase one share of Common Stock at an exercise price of $0.80 per share which will expire five years from the date of issuance (a "Series A Warrant") and (c) one half of a Series B warrant to purchase a share of Common Stock at an exercise price of $0.70 per share that will expire on June 30, 2026 (a "Series B Warrant"). F2 · ownership.nature: The securities are directly held by TCG Opportunity III LP. The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the Issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "Managing Partners"). F3 · ownership.nature: (Continued from Footnote 2) The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
April 05, 2024 Filed Apr 8, 2024 20:04 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	OtherCommon Stock	1,000	Not disclosed	Not disclosed	Disclosure SEC source: 0000950142-24-001001 · eh240467036_4-ngm2.xml · nonDerivative · entry 14 COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV GP, LP · CIK 0001796356 · 10% owner TCG IV GP, LLC · CIK 0001796359 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,000 F17 · price: At the Effective Time, Purchaser merged with and into the Issuer pursuant to Section 251(h) of the Delaware General Corporation Law, with the Issuer surviving as a wholly-owned subsidiary of the Parent. As a result, Parent holds all of the issued and outstanding shares of common stock (equaling 1,000 shares) of the Issuer. TCG LP owns 28.1% of Parent and is the general partner of Parent. Peter Svennilson and Dr. Goeddel are the managing partners of TCG GP, which is the general partner of TCG LP. F17 · ownership.nature: At the Effective Time, Purchaser merged with and into the Issuer pursuant to Section 251(h) of the Delaware General Corporation Law, with the Issuer surviving as a wholly-owned subsidiary of the Parent. As a result, Parent holds all of the issued and outstanding shares of common stock (equaling 1,000 shares) of the Issuer. TCG LP owns 28.1% of Parent and is the general partner of Parent. Peter Svennilson and Dr. Goeddel are the managing partners of TCG GP, which is the general partner of TCG LP. Read SEC document
April 05, 2024 Filed Apr 8, 2024 20:04 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	Disposition to issuerCommon Stock	44,000	Not disclosed	Not disclosed	Disclosure SEC source: 0000950142-24-001001 · eh240467036_4-ngm2.xml · nonDerivative · entry 13 COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV GP, LP · CIK 0001796356 · 10% owner TCG IV GP, LLC · CIK 0001796359 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · price: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2 · price: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F16 · ownership.nature: The securities were directly held by Peter Svennilson. Read SEC document
April 05, 2024 Filed Apr 8, 2024 20:04 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	Disposition to issuerCommon Stock	15,000	Not disclosed	Not disclosed	Disclosure SEC source: 0000950142-24-001001 · eh240467036_4-ngm2.xml · nonDerivative · entry 12 COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV GP, LP · CIK 0001796356 · 10% owner TCG IV GP, LLC · CIK 0001796359 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · price: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2 · price: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F15 · ownership.nature: The securities were owned solely by Tim Kutzkey. Read SEC document
April 05, 2024 Filed Apr 8, 2024 20:04 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	Disposition to issuerCommon Stock	100,000	Not disclosed	Not disclosed	Disclosure SEC source: 0000950142-24-001001 · eh240467036_4-ngm2.xml · nonDerivative · entry 11 COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV GP, LP · CIK 0001796356 · 10% owner TCG IV GP, LLC · CIK 0001796359 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · price: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2 · price: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F14 · ownership.nature: The securities were directly held by The Column Group Management LP ("TCGM LP"). The managing partners of TCGM LP are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. Each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
April 05, 2024 Filed Apr 8, 2024 20:04 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	Disposition to issuerCommon Stock	100,000	Not disclosed	Not disclosed	Disclosure SEC source: 0000950142-24-001001 · eh240467036_4-ngm2.xml · nonDerivative · entry 10 COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV GP, LP · CIK 0001796356 · 10% owner TCG IV GP, LLC · CIK 0001796359 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · price: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2 · price: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F13 · ownership.nature: The securities were directly held by TCG GP. The managing members of TCG GP are the TCG Managing Partners. The TCG Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. Each of the TCG Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
April 05, 2024 Filed Apr 8, 2024 20:04 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	Disposition to issuerCommon Stock	1,298,908	Not disclosed	Not disclosed	Disclosure SEC source: 0000950142-24-001001 · eh240467036_4-ngm2.xml · nonDerivative · entry 9 COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV GP, LP · CIK 0001796356 · 10% owner TCG IV GP, LLC · CIK 0001796359 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · price: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2 · price: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F12 · ownership.nature: The securities were directly held by Ponoi Capital II, LP ("Ponoi II LP"). Ponoi II Management, LLC ("Ponoi II LLC") is the general partner of Ponoi II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of Ponoi II LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. Ponoi II LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
April 05, 2024 Filed Apr 8, 2024 20:04 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	Disposition to issuerCommon Stock	1,298,908	Not disclosed	Not disclosed	Disclosure SEC source: 0000950142-24-001001 · eh240467036_4-ngm2.xml · nonDerivative · entry 8 COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV GP, LP · CIK 0001796356 · 10% owner TCG IV GP, LLC · CIK 0001796359 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · price: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2 · price: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F11 · ownership.nature: The securities were directly held by Ponoi Capital, LP ("Ponoi LP"). Ponoi Management, LLC ("Ponoi LLC") is the general partner of Ponoi LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of Ponoi LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. Ponoi LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
April 05, 2024 Filed Apr 8, 2024 20:04 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	Disposition to issuerCommon Stock	2,265,758	Not disclosed	Not disclosed	Disclosure SEC source: 0000950142-24-001001 · eh240467036_4-ngm2.xml · nonDerivative · entry 7 COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV GP, LP · CIK 0001796356 · 10% owner TCG IV GP, LLC · CIK 0001796359 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · price: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2 · price: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F10 · ownership.nature: The securities were directly held by The Column Group II, LP ("TCG II LP"). TCG II GP is the general partner of TCG II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG II GP are the TCG Managing Partners. The TCG Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG II GP and each of the TCG Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
April 05, 2024 Filed Apr 8, 2024 20:04 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	Disposition to issuerCommon Stock	968,990	Not disclosed	Not disclosed	Disclosure SEC source: 0000950142-24-001001 · eh240467036_4-ngm2.xml · nonDerivative · entry 6 COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV GP, LP · CIK 0001796356 · 10% owner TCG IV GP, LLC · CIK 0001796359 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · price: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2 · price: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F9 · ownership.nature: The securities were directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG III GP and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
April 05, 2024 Filed Apr 8, 2024 20:04 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	Disposition to issuerCommon Stock	858,035	Not disclosed	Not disclosed	Disclosure SEC source: 0000950142-24-001001 · eh240467036_4-ngm2.xml · nonDerivative · entry 5 COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV GP, LP · CIK 0001796356 · 10% owner TCG IV GP, LLC · CIK 0001796359 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · price: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2 · price: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F8 · ownership.nature: The securities were directly held by The Column Group III, LP ("TCG III LP"). The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG III GP and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
April 05, 2024 Filed Apr 8, 2024 20:04 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	Disposition to issuerCommon Stock	11,103,333	Not disclosed	Not disclosed	Disclosure SEC source: 0000950142-24-001001 · eh240467036_4-ngm2.xml · nonDerivative · entry 4 COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV GP, LP · CIK 0001796356 · 10% owner TCG IV GP, LLC · CIK 0001796359 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2 · price: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F7 · ownership.direct: The securities were directly held by The Column Group, LP ("TCG LP").The Column Group GP, LP ("TCG GP") is the general partner of TCG LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG GP are David Goeddel, a member of the Issuer's board of directors and Peter Svennilson (collectively, the "TCG Managing Partners"). The TCG Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG GP and each of the TCG Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
April 05, 2024 Filed Apr 8, 2024 20:04 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	Disposition to issuerCommon Stock	90,442	Not disclosed	Not disclosed	Disclosure SEC source: 0000950142-24-001001 · eh240467036_4-ngm2.xml · nonDerivative · entry 3 COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV GP, LP · CIK 0001796356 · 10% owner TCG IV GP, LLC · CIK 0001796359 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · price: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2 · price: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F6 · ownership.nature: The securities were directly held by The Column Group IV-A, LP ("TCG IV-A LP"). TCG IV GP LP is the general partner of TCG IV-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG IV LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
April 05, 2024 Filed Apr 8, 2024 20:04 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	Disposition to issuerCommon Stock	2,650,177	Not disclosed	Not disclosed	Disclosure SEC source: 0000950142-24-001001 · eh240467036_4-ngm2.xml · nonDerivative · entry 2 COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV GP, LP · CIK 0001796356 · 10% owner TCG IV GP, LLC · CIK 0001796359 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · price: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2 · price: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F5 · ownership.nature: The securities were directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG IV GP LLC ("TCG IV LLC") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG IV LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
April 05, 2024 Filed Apr 8, 2024 20:04 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	Disposition to issuerCommon Stock	949,862	Not disclosed	Not disclosed	Disclosure SEC source: 0000950142-24-001001 · eh240467036_4-ngm2.xml · nonDerivative · entry 1 COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV GP, LP · CIK 0001796356 · 10% owner TCG IV GP, LLC · CIK 0001796359 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 F1 · price: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2 · price: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F3 · ownership.nature: The securities were directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG Managing Members"). (cont'd in FN 3) F4 · ownership.nature: (cont'd from FN 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
April 04, 2024 Filed Apr 8, 2024 16:23 UTC	Surrozen, Inc./DE SRZN · Entity 6092	PurchaseSeries D Common Warrants · Derivative	397,773	Not disclosed Strike: $16.00	Not disclosed	Disclosure SEC source: 0000950170-24-042633 · ownership.xml · derivative · entry 10 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group III-A, LP Disclosed balance after: 397,773 Underlying: Common Stock · 397,773 shares Expires not disclosed F1 · price: Represents a price per unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which The Column Group III, LP ("TCG III LP") and The Column Group III-A, LP ("TCG III-A LP") purchased in the Issuer's private placement on April 4, 2024. F7 · derivative.exercise_date: These Series D Common Warrants are exercisable for 30 days following the Issuer's announcement of the enrollment of at least 50 patients in the SZN-043 Phase 2/3 clinical trial for the treatment of severe alcohol-associated hepatitis. The Series D Common Warrants will also become exercisable in the event of a Fundamental Transaction (as defined in the Series D Warrants). F7 · derivative.expiration_date: These Series D Common Warrants are exercisable for 30 days following the Issuer's announcement of the enrollment of at least 50 patients in the SZN-043 Phase 2/3 clinical trial for the treatment of severe alcohol-associated hepatitis. The Series D Common Warrants will also become exercisable in the event of a Fundamental Transaction (as defined in the Series D Warrants). F3 · ownership.nature: The securities are directly held by TCG III-A LP. TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
April 04, 2024 Filed Apr 8, 2024 16:23 UTC	Surrozen, Inc./DE SRZN · Entity 6092	PurchaseSeries D Common Warrants · Derivative	352,225	Not disclosed Strike: $16.00	Not disclosed	Disclosure SEC source: 0000950170-24-042633 · ownership.xml · derivative · entry 9 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group III, LP Disclosed balance after: 352,225 Underlying: Common Stock · 352,225 shares Expires not disclosed F1 · price: Represents a price per unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which The Column Group III, LP ("TCG III LP") and The Column Group III-A, LP ("TCG III-A LP") purchased in the Issuer's private placement on April 4, 2024. F7 · derivative.exercise_date: These Series D Common Warrants are exercisable for 30 days following the Issuer's announcement of the enrollment of at least 50 patients in the SZN-043 Phase 2/3 clinical trial for the treatment of severe alcohol-associated hepatitis. The Series D Common Warrants will also become exercisable in the event of a Fundamental Transaction (as defined in the Series D Warrants). F7 · derivative.expiration_date: These Series D Common Warrants are exercisable for 30 days following the Issuer's announcement of the enrollment of at least 50 patients in the SZN-043 Phase 2/3 clinical trial for the treatment of severe alcohol-associated hepatitis. The Series D Common Warrants will also become exercisable in the event of a Fundamental Transaction (as defined in the Series D Warrants). F2 · ownership.nature: The securities are directly held by TCG III LP. The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
April 04, 2024 Filed Apr 8, 2024 16:23 UTC	Surrozen, Inc./DE SRZN · Entity 6092	PurchaseSeries C Common Warrants · Derivative	397,773	Not disclosed Strike: $16.00	Not disclosed	Disclosure SEC source: 0000950170-24-042633 · ownership.xml · derivative · entry 8 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group III-A, LP Disclosed balance after: 397,773 Underlying: Common Stock · 397,773 shares Expires not disclosed F1 · price: Represents a price per unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which The Column Group III, LP ("TCG III LP") and The Column Group III-A, LP ("TCG III-A LP") purchased in the Issuer's private placement on April 4, 2024. F6 · derivative.exercise_date: These Series C Common Warrants are exercisable for 30 days following the Issuer's announcement of final data from the SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis. The Series C Common Warrants will also become exercisable in the event of a Fundamental Transaction (as defined in the Series C Warrants). F6 · derivative.expiration_date: These Series C Common Warrants are exercisable for 30 days following the Issuer's announcement of final data from the SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis. The Series C Common Warrants will also become exercisable in the event of a Fundamental Transaction (as defined in the Series C Warrants). F3 · ownership.nature: The securities are directly held by TCG III-A LP. TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
April 04, 2024 Filed Apr 8, 2024 16:23 UTC	Surrozen, Inc./DE SRZN · Entity 6092	PurchaseSeries C Common Warrants · Derivative	352,225	Not disclosed Strike: $16.00	Not disclosed	Disclosure SEC source: 0000950170-24-042633 · ownership.xml · derivative · entry 7 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group III, LP Disclosed balance after: 352,225 Underlying: Common Stock · 352,225 shares Expires not disclosed F1 · price: Represents a price per unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which The Column Group III, LP ("TCG III LP") and The Column Group III-A, LP ("TCG III-A LP") purchased in the Issuer's private placement on April 4, 2024. F6 · derivative.exercise_date: These Series C Common Warrants are exercisable for 30 days following the Issuer's announcement of final data from the SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis. The Series C Common Warrants will also become exercisable in the event of a Fundamental Transaction (as defined in the Series C Warrants). F6 · derivative.expiration_date: These Series C Common Warrants are exercisable for 30 days following the Issuer's announcement of final data from the SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis. The Series C Common Warrants will also become exercisable in the event of a Fundamental Transaction (as defined in the Series C Warrants). F2 · ownership.nature: The securities are directly held by TCG III LP. The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
April 04, 2024 Filed Apr 8, 2024 16:23 UTC	Surrozen, Inc./DE SRZN · Entity 6092	PurchaseSeries B Common Warrants · Derivative	111,656	Not disclosed Strike: $14.25	Not disclosed	Disclosure SEC source: 0000950170-24-042633 · ownership.xml · derivative · entry 6 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group III-A, LP Disclosed balance after: 111,656 Underlying: Common Stock · 111,656 shares Expires not disclosed F1 · price: Represents a price per unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which The Column Group III, LP ("TCG III LP") and The Column Group III-A, LP ("TCG III-A LP") purchased in the Issuer's private placement on April 4, 2024. F5 · derivative.exercise_date: These Series B Common Warrants are exercisable immediately upon issuance and expire on the fifth trading day following the Issuer's announcement that (i) it has completed the enrollment of at least 15 patients with a 30-day mortality rate less than 30% in the Issuer's SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis, with no recommended changes by the Safety Review Committee to the study design, including changes related to dose or schedule, and (ii) Safety Review Committee approval for the Issuer to advance to a higher dose cohort. F5 · derivative.expiration_date: These Series B Common Warrants are exercisable immediately upon issuance and expire on the fifth trading day following the Issuer's announcement that (i) it has completed the enrollment of at least 15 patients with a 30-day mortality rate less than 30% in the Issuer's SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis, with no recommended changes by the Safety Review Committee to the study design, including changes related to dose or schedule, and (ii) Safety Review Committee approval for the Issuer to advance to a higher dose cohort. F3 · ownership.nature: The securities are directly held by TCG III-A LP. TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
April 04, 2024 Filed Apr 8, 2024 16:23 UTC	Surrozen, Inc./DE SRZN · Entity 6092	PurchaseSeries B Common Warrants · Derivative	98,870	Not disclosed Strike: $14.25	Not disclosed	Disclosure SEC source: 0000950170-24-042633 · ownership.xml · derivative · entry 5 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group III, LP Disclosed balance after: 98,870 Underlying: Common Stock · 98,870 shares Expires not disclosed F1 · price: Represents a price per unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which The Column Group III, LP ("TCG III LP") and The Column Group III-A, LP ("TCG III-A LP") purchased in the Issuer's private placement on April 4, 2024. F5 · derivative.exercise_date: These Series B Common Warrants are exercisable immediately upon issuance and expire on the fifth trading day following the Issuer's announcement that (i) it has completed the enrollment of at least 15 patients with a 30-day mortality rate less than 30% in the Issuer's SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis, with no recommended changes by the Safety Review Committee to the study design, including changes related to dose or schedule, and (ii) Safety Review Committee approval for the Issuer to advance to a higher dose cohort. F5 · derivative.expiration_date: These Series B Common Warrants are exercisable immediately upon issuance and expire on the fifth trading day following the Issuer's announcement that (i) it has completed the enrollment of at least 15 patients with a 30-day mortality rate less than 30% in the Issuer's SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis, with no recommended changes by the Safety Review Committee to the study design, including changes related to dose or schedule, and (ii) Safety Review Committee approval for the Issuer to advance to a higher dose cohort. F2 · ownership.nature: The securities are directly held by TCG III LP. The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
April 04, 2024 Filed Apr 8, 2024 16:23 UTC	Surrozen, Inc./DE SRZN · Entity 6092	PurchaseSeries A Common Warrants · Derivative	102,651	Not disclosed Strike: $15.50	Not disclosed	Disclosure SEC source: 0000950170-24-042633 · ownership.xml · derivative · entry 4 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group III-A, LP Disclosed balance after: 102,651 Underlying: Common Stock · 102,651 shares Expires not disclosed F1 · price: Represents a price per unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which The Column Group III, LP ("TCG III LP") and The Column Group III-A, LP ("TCG III-A LP") purchased in the Issuer's private placement on April 4, 2024. F4 · derivative.exercise_date: These Series A Common Warrants are immediately exercisable and expire on April 4, 2029. F4 · derivative.expiration_date: These Series A Common Warrants are immediately exercisable and expire on April 4, 2029. F3 · ownership.nature: The securities are directly held by TCG III-A LP. TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
April 04, 2024 Filed Apr 8, 2024 16:23 UTC	Surrozen, Inc./DE SRZN · Entity 6092	PurchaseSeries A Common Warrants · Derivative	90,897	Not disclosed Strike: $15.50	Not disclosed	Disclosure SEC source: 0000950170-24-042633 · ownership.xml · derivative · entry 3 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group III, LP Disclosed balance after: 90,897 Underlying: Common Stock · 90,897 shares Expires not disclosed F1 · price: Represents a price per unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which The Column Group III, LP ("TCG III LP") and The Column Group III-A, LP ("TCG III-A LP") purchased in the Issuer's private placement on April 4, 2024. F4 · derivative.exercise_date: These Series A Common Warrants are immediately exercisable and expire on April 4, 2029. F4 · derivative.expiration_date: These Series A Common Warrants are immediately exercisable and expire on April 4, 2029. F2 · ownership.nature: The securities are directly held by TCG III LP. The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
April 04, 2024 Filed Apr 8, 2024 16:23 UTC	Surrozen, Inc./DE SRZN · Entity 6092	PurchaseCommon Stock	102,651	$15.50	$1,591,090.50	Disclosure SEC source: 0000950170-24-042633 · ownership.xml · nonDerivative · entry 2 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group III-A, LP Disclosed balance after: 332,885 F1 · price: Represents a price per unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which The Column Group III, LP ("TCG III LP") and The Column Group III-A, LP ("TCG III-A LP") purchased in the Issuer's private placement on April 4, 2024. F3 · ownership.nature: The securities are directly held by TCG III-A LP. TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
April 04, 2024 Filed Apr 8, 2024 16:23 UTC	Surrozen, Inc./DE SRZN · Entity 6092	PurchaseCommon Stock	90,897	$15.50	$1,408,903.50	Disclosure SEC source: 0000950170-24-042633 · ownership.xml · nonDerivative · entry 1 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group III, LP Disclosed balance after: 294,767 F1 · price: Represents a price per unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which The Column Group III, LP ("TCG III LP") and The Column Group III-A, LP ("TCG III-A LP") purchased in the Issuer's private placement on April 4, 2024. F2 · ownership.nature: The securities are directly held by TCG III LP. The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
April 04, 2024 Filed Apr 17, 2024 16:14 UTC Amendment	Surrozen, Inc./DE SRZN · Entity 6092	PurchaseCommon Stock	102,651	$15.50	$1,591,090.50	Disclosure SEC source: 0000950170-24-045118 · ownership.xml · nonDerivative · entry 2 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group III-A, LP Disclosed balance after: 326,992 F1 · price: Represents a price per unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which The Column Group III, LP ("TCG III LP") and The Column Group III-A, LP ("TCG III-A LP") purchased in the Issuer's private placement on April 4, 2024. F2 · balance_after: This Form 4/A is being filed to correct the amount beneficially owned by the Reporting Person, which was misreported in the original Form 4 filed on April 8, 2024 due to an administrative error. F4 · ownership.nature: The securities are directly held by TCG III-A LP. TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
April 04, 2024 Filed Apr 17, 2024 16:14 UTC Amendment	Surrozen, Inc./DE SRZN · Entity 6092	PurchaseCommon Stock	90,897	$15.50	$1,408,903.50	Disclosure SEC source: 0000950170-24-045118 · ownership.xml · nonDerivative · entry 1 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group III, LP Disclosed balance after: 289,549 F1 · price: Represents a price per unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which The Column Group III, LP ("TCG III LP") and The Column Group III-A, LP ("TCG III-A LP") purchased in the Issuer's private placement on April 4, 2024. F2 · balance_after: This Form 4/A is being filed to correct the amount beneficially owned by the Reporting Person, which was misreported in the original Form 4 filed on April 8, 2024 due to an administrative error. F3 · ownership.nature: The securities are directly held by TCG III LP. The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
February 12, 2024 Filed Feb 14, 2024 16:15 UTC	Tenaya Therapeutics, Inc. TNYA · Entity 6506	PurchaseCommon Stock	2,222,222	$4.50	$9,999,999.00	Disclosure SEC source: 0000950170-24-015234 · ownership.xml · nonDerivative · entry 1 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 13,599,275 F1 · ownership.nature: The securities are directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "Managing Partners"). F2 · ownership.nature: (Continued from Footnote 1) The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
November 16, 2023 Filed Nov 17, 2023 16:30 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	5,840	$0.62	$3,627.22	Disclosure SEC source: 0000950170-23-064854 · ownership.xml · nonDerivative · entry 2 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV GP, LP · CIK 0001796356 · 10% owner TCG IV GP, LLC · CIK 0001796359 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 949,862 F4 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $0.6198 to $0.6221, inclusive. The Reporting Persons undertake to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 4 to this Form 4. F2 · ownership.nature: The securities are directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG Managing Members"). F3 · ownership.nature: (Continued from Footnote 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
November 15, 2023 Filed Nov 17, 2023 16:30 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	16,791	$0.71	$11,879.63	Disclosure SEC source: 0000950170-23-064854 · ownership.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV GP, LP · CIK 0001796356 · 10% owner TCG IV GP, LLC · CIK 0001796359 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 944,022 F1 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $0.681 to $0.7201, inclusive. The Reporting Persons undertake to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 1 to this Form 4. F2 · ownership.nature: The securities are directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG Managing Members"). F3 · ownership.nature: (Continued from Footnote 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
March 10, 2023 Filed Mar 14, 2023 16:12 UTC	Tenaya Therapeutics, Inc. TNYA · Entity 6506	PurchaseCommon Stock	6,779	$2.60	$17,595.57	Disclosure SEC source: 0000899243-23-008390 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 11,377,053 F1 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $2.58 to $2.60, inclusive. The Reporting Persons undertake to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 1 to this Form 4. F2 · ownership.nature: The securities are directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "Managing Partners"). F3 · ownership.nature: (Continued from Footnote 2) The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
February 08, 2023 Filed Feb 10, 2023 16:32 UTC	Tenaya Therapeutics, Inc. TNYA · Entity 6506	PurchaseCommon Stock	1,500,000	$2.60	$3,900,000.00	Disclosure SEC source: 0000899243-23-004584 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 11,370,274 F1 · ownership.nature: The securities are directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "Managing Partners"). F2 · ownership.nature: (Continued from Footnote 1) The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
January 31, 2023 Filed Feb 1, 2023 16:50 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	176,730	$5.00	$883,402.58	Disclosure SEC source: 0000899243-23-003137 · doc4.xml · nonDerivative · entry 2 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV GP, LP · CIK 0001796356 · 10% owner TCG IV GP, LLC · CIK 0001796359 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 927,231 F4 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $4.995 to $5.00, inclusive. The Reporting Persons undertake to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 4 to this Form 4. F2 · ownership.nature: The securities are directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG Managing Members"). F3 · ownership.nature: (Continued from Footnote 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
January 30, 2023 Filed Feb 1, 2023 16:50 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	7,542	$5.00	$37,706.98	Disclosure SEC source: 0000899243-23-003137 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV GP, LP · CIK 0001796356 · 10% owner TCG IV GP, LLC · CIK 0001796359 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 750,501 F1 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $4.99 to $5.00, inclusive. The Reporting Persons undertake to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 1 to this Form 4. F2 · ownership.nature: The securities are directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG Managing Members"). F3 · ownership.nature: (Continued from Footnote 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
January 23, 2023 Filed Jan 25, 2023 16:35 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	9,900	$5.00	$49,494.06	Disclosure SEC source: 0000899243-23-002637 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV GP, LP · CIK 0001796356 · 10% owner TCG IV GP, LLC · CIK 0001796359 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 742,959 F1 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $4.995 to $5.00, inclusive. The Reporting Persons undertake to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 1 to this Form 4. F2 · ownership.nature: The securities are directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG Managing Members"). F3 · ownership.nature: (Continued from Footnote 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
January 20, 2023 Filed Jan 23, 2023 16:22 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	500	$5.00	$2,498.00	Disclosure SEC source: 0000899243-23-002380 · doc4.xml · nonDerivative · entry 2 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV GP, LP · CIK 0001796356 · 10% owner TCG IV GP, LLC · CIK 0001796359 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 733,059 F4 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $4.98 to $5.00, inclusive. The Reporting Persons undertake to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 4 to this Form 4. F2 · ownership.nature: The securities are directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG Managing Members"). F3 · ownership.nature: (Continued from Footnote 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
January 19, 2023 Filed Jan 23, 2023 16:22 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	37,639	$5.00	$188,104.67	Disclosure SEC source: 0000899243-23-002380 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV GP, LP · CIK 0001796356 · 10% owner TCG IV GP, LLC · CIK 0001796359 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 732,559 F1 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $4.975 to $5.00, inclusive. The Reporting Persons undertake to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 1 to this Form 4. F2 · ownership.nature: The securities are directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG Managing Members"). F3 · ownership.nature: (Continued from Footnote 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
January 19, 2023 Filed Jan 23, 2023 16:25 UTC	Tenaya Therapeutics, Inc. TNYA · Entity 6506	PurchaseCommon Stock	69,739	$2.50	$174,201.05	Disclosure SEC source: 0000899243-23-002382 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 9,870,274 F1 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $2.35 to $2.57, inclusive. The Reporting Persons undertake to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 1 to this Form 4. F2 · ownership.nature: The securities are directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "Managing Partners"). F3 · ownership.nature: (Continued from Footnote 2) The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
January 18, 2023 Filed Jan 19, 2023 16:18 UTC	Tenaya Therapeutics, Inc. TNYA · Entity 6506	PurchaseCommon Stock	135,688	$2.52	$341,431.71	Disclosure SEC source: 0000899243-23-002161 · doc4.xml · nonDerivative · entry 2 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 9,800,535 F4 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $2.37 to $2.60, inclusive. The Reporting Persons undertake to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 4 to this Form 4. F2 · ownership.nature: The securities are directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "Managing Partners"). F3 · ownership.nature: (Continued from Footnote 2) The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
January 17, 2023 Filed Jan 19, 2023 16:18 UTC	Tenaya Therapeutics, Inc. TNYA · Entity 6506	PurchaseCommon Stock	49,463	$2.49	$123,395.35	Disclosure SEC source: 0000899243-23-002161 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 9,664,847 F1 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $2.32 to $2.60, inclusive. The Reporting Persons undertake to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 1 to this Form 4. F2 · ownership.nature: The securities are directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "Managing Partners"). F3 · ownership.nature: (Continued from Footnote 2) The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
January 12, 2023 Filed Jan 17, 2023 16:34 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	5,378	$4.95	$26,602.81	Disclosure SEC source: 0000899243-23-001855 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV GP, LP · CIK 0001796356 · 10% owner TCG IV GP, LLC · CIK 0001796359 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 694,920 F1 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $4.77 to $5.00, inclusive. The Reporting Persons undertake to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 1 to this Form 4. F2 · ownership.nature: The securities are directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG Managing Members"). F3 · ownership.nature: (Continued from Footnote 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
January 11, 2023 Filed Jan 12, 2023 16:37 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	209,000	$4.76	$994,840.00	Disclosure SEC source: 0000899243-23-001695 · doc4.xml · nonDerivative · entry 2 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV GP, LP · CIK 0001796356 · 10% owner TCG IV GP, LLC · CIK 0001796359 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 689,542 F2 · ownership.nature: The securities are directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG Managing Members"). F3 · ownership.nature: (Continued from Footnote 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
January 10, 2023 Filed Jan 12, 2023 16:37 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	100,070	$4.84	$484,518.93	Disclosure SEC source: 0000899243-23-001695 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV GP, LP · CIK 0001796356 · 10% owner TCG IV GP, LLC · CIK 0001796359 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 480,542 F1 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $4.70 to $4.98, inclusive. The Reporting Persons undertake to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 1 to this Form 4. F2 · ownership.nature: The securities are directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG Managing Members"). F3 · ownership.nature: (Continued from Footnote 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
December 12, 2022 Filed Dec 14, 2022 16:29 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	300	$4.98	$1,493.01	Disclosure SEC source: 0000899243-22-038466 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV GP, LP · CIK 0001796356 · 10% owner TCG IV GP, LLC · CIK 0001796359 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 380,472 F1 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $4.97 to $4.98, inclusive. The Reporting Persons undertake to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 1 to this Form 4. F2 · ownership.nature: The securities are directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG Managing Members"). F3 · ownership.nature: (Continued from Footnote 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
November 22, 2022 Filed Nov 23, 2022 16:17 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	4,330	$5.00	$21,646.10	Disclosure SEC source: 0000899243-22-036916 · doc4.xml · nonDerivative · entry 2 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV GP, LP · CIK 0001796356 · 10% owner TCG IV GP, LLC · CIK 0001796359 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 380,172 F4 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $4.98 to $5.00, inclusive. The Reporting Persons undertake to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 4 to this Form 4. F2 · ownership.nature: The securities are directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG Managing Members"). F3 · ownership.nature: (Continued from Footnote 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
November 21, 2022 Filed Nov 23, 2022 16:17 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	35,997	$5.00	$179,941.80	Disclosure SEC source: 0000899243-22-036916 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV GP, LP · CIK 0001796356 · 10% owner TCG IV GP, LLC · CIK 0001796359 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 375,842 F1 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $4.98 to $5.00, inclusive. The Reporting Persons undertake to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 1 to this Form 4. F2 · ownership.nature: The securities are directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG Managing Members"). F3 · ownership.nature: (Continued from Footnote 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
November 21, 2022 Filed Nov 23, 2022 16:12 UTC	Tenaya Therapeutics, Inc. TNYA · Entity 6506	PurchaseCommon Stock	9,615,384	$2.60	$24,999,998.40	Disclosure SEC source: 0000899243-22-036910 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 9,615,384 F1 · ownership.nature: The securities are directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "Managing Partners"). F2 · ownership.nature: (Continued from Footnote 1) The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.